13-valent Pneumococcal Conjugate Vaccine

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Vaccines, Pneumococcal Conjugate Vaccine

Conditions

Vaccines, Pneumococcal Conjugate Vaccine

Trial Timeline

Sep 1, 2005 → Feb 1, 2007

NCT ID

NCT00269672

About 13-valent Pneumococcal Conjugate Vaccine

13-valent Pneumococcal Conjugate Vaccine is a phase 2 stage product being developed by Pfizer for Vaccines, Pneumococcal Conjugate Vaccine. The current trial status is completed. This product is registered under clinical trial identifier NCT00269672. Target conditions include Vaccines, Pneumococcal Conjugate Vaccine.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05329259	Approved	Completed	Oct 6, 2022	Nov 30, 2022	Pneumococcal Disease
NCT03571607	Phase 3	Completed	Jul 12, 2018	Nov 16, 2018	Pneumococcal Infections
NCT02034877	Approved	Completed	Aug 1, 2014	Jul 1, 2015	Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
NCT01026038	Phase 3	Completed	Apr 1, 2010	Nov 1, 2010	13-valent Pneumococcal Vaccine
NCT00963235	Phase 3	Completed	Nov 1, 2009	May 1, 2012	HIV Infections
NCT00708682	Phase 3	Completed	Jul 1, 2008	May 1, 2010	Vaccines, Pneumococcal
NCT00500357	Phase 3	Completed	Nov 1, 2007	Jan 1, 2010	Vaccines, Pneumococcal Conjugate Vaccine
NCT00452452	Phase 3	Completed	Jul 1, 2007	Mar 1, 2008	Pneumococcal Infections
NCT00464945	Phase 3	Completed	Jun 1, 2007	Sep 1, 2008	Pneumococcal Vaccines
NCT00269672	Phase 2	Completed	Sep 1, 2005	Feb 1, 2007	Vaccines, Pneumococcal Conjugate Vaccine

Competing Products

20 competing products in Vaccines, Pneumococcal Conjugate Vaccine

See all competitors

Product	Company	Stage	Hype Score
Vaxelis™	Merck	Approved	85
21-valent pneumococcal conjugate vaccine	Merck	Approved	85
Gardasil-9	Merck	Approved	85
Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinant	Merck	Approved	85
13-valent pneumococcal conjugate vaccine + 7-valent pneumococcal conjugate vaccine	Pfizer	Phase 3	76
13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccine	Pfizer	Phase 3	76
13vPnC + 23vPS	Pfizer	Phase 3	76
13-valent Pneumococcal Conjugate Vaccine	Pfizer	Phase 3	76
pneumococcus conjugate vaccine 7 valent to reduce carriage	Pfizer	Approved	84
13-valent Pneumococcal Conjugate Vaccine + 7vPnC	Pfizer	Phase 3	76
13-valent Pneumococcal Conjugate Vaccine + 7vPnC + Pediacel + NeisVac-C + Menitorix	Pfizer	Phase 3	76
rLP2086 + MCV4 + Tdap + MCV4 + Tdap + saline + rLP2086 + saline	Pfizer	Phase 2	51
13 valent pneumococcal conjugate vaccine + 7vPnc pneumococcal conjugate vaccine	Pfizer	Phase 3	76
13vPnC	Pfizer	Approved	84
13-valent pneumococcal conjugate vaccine + 7-valent pneumococcal conjugate vaccine + Pentavac	Pfizer	Phase 3	76
pneumococcus conjugate vaccine	Pfizer	Approved	84
13 valent Pneumococcal Conjugate Vaccine + 13 valent Pneumococcal Conjugate Vaccine + 13 valent Pneumococcal Conjugate Vaccine + 23-valent Pneumococcal Polysaccharide Vaccine + 23-valent Pneumococcal Polysaccharide Vaccine	Pfizer	Phase 3	76
Prevenar + Infanrix hexa	Pfizer	Approved	84
13vPnC	Pfizer	Approved	84
13 valent pneumococcal conjugate vaccine with Polysorbate 80 + 13 valent pneumococcal conjugate vaccine without Polysorbate 80	Pfizer	Phase 3	76

Other Products from Pfizer